Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,449 shares of the biopharmaceutical company’s stock after selling 1,123 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $11,715,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of REGN. BlackRock Inc. purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $5,682,636,000. Legal & General Group Plc purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $473,872,000. Bank of New York Mellon Corp purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $472,950,000. Deutsche Bank AG purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $323,249,000. Finally, Man Group plc acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $272,460,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 31.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company’s stock, valued at approximately $512,550. This trade represents a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 8,093 shares of company stock valued at $6,506,845. Company insiders own 6.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on REGN shares. The Goldman Sachs Group boosted their price objective on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a report on Friday, July 31st. BMO Capital Markets raised their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Wells Fargo & Company raised their target price on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Morgan Stanley lifted their price target on Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Finally, Royal Bank Of Canada boosted their price target on Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the company a “sector perform” rating in a research note on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $845.59.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $807.48 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $572.75 and a twelve month high of $859.34. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The company has a market cap of $83.14 billion, a PE ratio of 19.96, a price-to-earnings-growth ratio of 1.35 and a beta of 0.16. The company’s 50 day moving average is $791.41 and its 200 day moving average is $721.87.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the business posted $12.81 EPS. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 47.98 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were given a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.